Updated:
Novotech
Novotech is a global full-service clinical research organization (CRO) and scientific advisory partner for biotech and small to mid-sized pharma companies.
Novotech
Novotech is a global full-service clinical research organization (CRO) and scientific advisory partner for biotech and small to mid-sized pharma companies.
General information
Firm type
Asset Manager
Year founded
1997
Location
Region
Europe
Country
Singapore
City
Singapore
Corporate office
Singapore, Singapore
Additional offices
Sydney, Australia · Warsaw, Poland · Bucharest, Romania · Boulder, United States · San Francisco, United States · Shanghai, China · Beijing, China · Seoul, South Korea · Bangalore, India · Cologne, Germany · Madrid, Spain · London, UK (implied by Europe offices)
Sector focus
Frequently asked questions
Who owns Novotech?
Novotech is owned by a consortium of investors led by TPG, which acquired a controlling stake in the company, along with GIC and Temasek, two major Singapore sovereign wealth funds. These investors supported the merger of Novotech Group and PPC Group to form Novotech Health Holdings.
What clinical trial phases does Novotech cover?
Novotech covers all phases of clinical development, from first-in-human and early-phase studies through to Phase III and regulatory submission. The company has particular expertise in early-phase oncology and rare disease studies conducted in Australia, where regulatory pathways are faster.
In which therapeutic areas does Novotech specialize?
Novotech's stated therapeutic specializations include oncology, liver disease, infectious diseases and vaccines, orphan and rare diseases, and radiopharmaceuticals. It also offers services across general medicine through its broad CRO operations.
Does Novotech operate only in Asia-Pacific?
No. Novotech operates across more than 30 office locations in Asia-Pacific, Europe, North America, Africa, and the Middle East. Its global footprint includes offices in the US, Poland, Germany, Spain, India, South Korea, China, and Australia, among others.
What is Novotech's relationship with Acrostar?
Acrostar is Novotech's Site Management Organization (SMO) division. It operates as a dedicated entity providing clinical trial site management services, complementing Novotech's broader CRO offerings.
How does Novotech differentiate from other large CROs?
Novotech positions itself as an Asia-Pacific-originated global CRO with deep regional expertise, particularly in Australia's fast early-phase regulatory environment. Its ownership by TPG, GIC, and Temasek provides strategic capital for acquisitions and expansion, setting it apart from publicly traded or private-equity-only competitors.
What recent acquisitions has Novotech made?
Notable acquisitions include EastHORN (Europe), NCGS (US), and CBR International (US). Novotech also took minority stakes in ObvioHealth (decentralized clinical trials) and Prospection (health analytics). The company merged with PPC Group to form Novotech Health Holdings.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: